Xilio Therapeutics Inc (XLO): Next-Year EPS Estimate 46.48%
As of 2026-11-12, Xilio Therapeutics Inc (XLO) has a next-year EPS growth estimate of 46.48%. Featured in our EPS revision report on 2026-11-03.
On 2026-11-11, analyst consensus for XLO's next-year EPS growth shifted from 31.09% to 46.48% — a positive change of 15.39 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at 45.82%.
What's Driving This
XLO has been
Generated 2026-11-11 from news as of 2026-11-11
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 46.48%
- EPS growth this year
- 45.82%
- EPS next quarter (est)
- -$0.78
- Last price
- $8.24
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-12 | 46.48% | 45.82% | -$0.78 | $8.24 |
| 2026-11-11 | 46.48% | 45.82% | -$0.78 | $8.47 |
| 2026-11-10 | 31.09% | 31.30% | -$0.97 | $8.53 |
| 2026-11-09 | 31.09% | 31.30% | -$0.94 | $9.00 |
| 2026-11-07 | 31.09% | 31.30% | -$0.94 | $8.62 |
| 2026-11-06 | 31.09% | 31.30% | -$0.94 | $8.62 |
| 2026-11-05 | 31.09% | 31.30% | -$0.94 | $8.50 |
| 2026-11-04 | 31.09% | 31.30% | -$0.94 | $8.71 |
| 2026-11-03 | 31.09% | 31.30% | -$0.94 | $8.68 |
| 2026-11-02 | 31.09% | 31.30% | -$0.94 | $7.99 |
| 2026-10-31 | 31.09% | 31.30% | -$0.94 | $8.03 |
| 2026-10-30 | 31.09% | 31.30% | -$0.94 | $8.03 |
| 2026-10-29 | 31.09% | 31.30% | -$0.94 | $7.77 |
| 2026-10-28 | 31.09% | 31.30% | -$0.94 | $8.01 |
| 2026-10-27 | 31.09% | 31.30% | -$0.94 | $8.01 |
| 2026-10-26 | 31.09% | 31.30% | -$0.94 | $7.31 |
| 2026-10-23 | 31.08% | 31.26% | -$0.94 | $7.57 |
| 2026-10-22 | 31.08% | 31.26% | -$0.94 | $8.03 |
| 2026-10-21 | 31.08% | 31.26% | -$0.94 | $8.43 |
| 2026-05-12 | 115.06% | 42.96% | -$0.58 | $7.73 |
| 2026-05-11 | 115.06% | 42.96% | -$0.66 | $7.73 |
| 2026-05-10 | 115.06% | 42.96% | -$0.66 | $7.74 |
| 2026-05-07 | 115.06% | 42.96% | -$0.66 | $7.81 |
| 2026-05-06 | 115.06% | 42.96% | -$0.66 | $7.90 |
| 2026-05-05 | 115.06% | 42.96% | -$0.66 | $7.71 |
| 2026-05-04 | 115.06% | 42.96% | -$0.66 | $8.33 |
| 2026-05-03 | 115.06% | 42.96% | -$0.66 | $8.32 |
| 2026-04-30 | 115.06% | 42.96% | -$0.66 | $7.92 |
| 2026-04-29 | 115.06% | 42.96% | -$0.66 | $7.79 |
| 2026-04-28 | 115.06% | 42.96% | -$0.66 | $7.92 |
Reports Featuring XLO
Recent News
- Xilio Therapeutics Reports Third Quarter 2026 Financial Results and Provides Pipeline and Business UpdatesGlobeNewswire
- Xilio Therapeutics to Present at the Stifel 2026 Healthcare ConferenceGlobeNewswire
- Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLCGlobeNewswire
- Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
Screen Performance
Aggregate stats across all 2145 tickers our top-EPS-revision screen has flagged over the past 225 days.
- Median return since detection
- -2.9%
- % of tickers in the green
- 43%
- Median return on winners
- +22.8%
- Large revisions captured
- 2246
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Xilio Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-11-12, Xilio Therapeutics Inc (XLO) has a next-year EPS growth estimate of 46.48%, based on analyst consensus.
When was the latest EPS estimate revision for XLO?▾
The most recent revision occurred on 2026-11-11, when analysts adjusted the next-year EPS growth estimate from 31.09% to 46.48%.
What sector and industry does Xilio Therapeutics Inc belong to?▾
Xilio Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. XLO appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Xilio Therapeutics Inc (XLO) appears here because it was detected by our daily top-EPS-revision-performer screen.